Breast Cancer

The breast cancer expert discussed the implications of this approval, as well as the data that led to the approval of sacituzumab govitecan-hziy.

This study found a substantial difference in the number of agents available for use in the metastatic and adjuvant settings for non-small cell lung cancer, breast cancer, and colon cancer.

Brendan F. Kennedy, PhD, discussed this study which evaluated the accuracy of quantitative micro-elastography compared to optical coherence tomography.

The FDA granted a breakthrough therapy designation and priority review under its Accelerated Approval Program to sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer.

Identifying early predictors of poor quality of life could allow for the identification of patients who may benefit from early referral to palliative and supportive care according to the researchers.

A prognostic survival model, titled PROVIEW, was able to accurately predict changing cancer survival risk over time and may have the potential to be a useful prognostic tool that can be completed by patients.

The FDA approved tucatinib in combination with chemotherapy for the treatment of adult patients with advanced forms of HER2-positive breast cancer.

This study examined delayed targeted intraoperative radiotherapy vs external beam radiotherapy to determine how it impacted patients with breast cancer, finding no statically significant decrease in mastectomy-free survival, distant-disease survival or overall survival.

A group of expert medical societies developed joint recommendations for healthcare professionals and patients to guide the prioritization, treatment and triage of breast cancer during the COVID-19 pandemic.

Given that these features are associated with breast cancer risk and could improve the detection of short-term risk of breast cancer, the authors suggested that further investigation of common loci is necessary.

The decision to halt the study was based on the unanimous recommendation by an independent data safety monitoring committee during its routine review of the ASCENT study.

Experts provide perspective on the rapidly changing landscape of targeted therapies in breast cancer treatment, and the importance of matching the right agent with the right patient.

ONCOLOGY® recently sat down with Joyce A. O’Shaughnessy, MD, to discuss the recent trends in breast cancer treatment and the avalanche of agents moving through the development pipeline that have the potential to redefine the accepted standards of care.

CytoDyn announced that it has enrolled and treated the first 2 patients with COVID-19 with leronlimab under its phase II randomized clinical trial.

Plastic surgeon and breast specialist Dr. Constance Chen discussed the potential complications of implant-based breast reconstruction, and how it compares to natural tissue reconstruction.

Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.

In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.

This study examined the association of disease progression and the deterioration of health-related quality of life for patients with metastatic breast, pancreatic, lung, and colorectal cancer.

Breast cancer incidence in women aged 25 to 39 has been steadily increasing for the last 80 years, though researchers indicated that this increase cannot be attributed to changes in parity over time.

This study found significant increases in the first year, which eventually decreased in following years, regarding sickness absence and disability pensions days after a 2010 breast cancer diagnosis.

This study suggested that PV prevalence among postmenopausal women may be high enough to warrant testing even in the absence of early diagnosis age or family history.

This study assessed whether the accumulative, static, or dynamic method was best suited for determining the familial risk of breast cancer.

Tracking large numbers of individualized tumor mutations in cell-free DNA improved minimal residual disease detection in breast cancer patients, though the sensitivity is driven by the number of mutations available to track.

A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.

A recent study found that young women aged 18-39 diagnosed with breast cancer typically suffer through financial hardships regardless of outstanding life circumstances such as career and insurance coverage.